X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.globenewswire.com/news-release/2023/10/08/2756367/0/en/New-Safety-Data-Suggests-SPRAVATO-Esketamine-Nasal-Spray-is-More-Tolerable-and-Effective-Compared-to-Quetiapine-Extended-Release-XR-in-Adults-with-Treatment-resistant-Major-Depress.html
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-esketamine-hydrochloride-49242.pdf
https://www.yicaiglobal.com/news/china-approves-sales-of-janssen-antidepressant#:~:text=(Yicai%20Global)%20April%2021%20%2D%2D,new%20antidepressant%20in%20the%20country.
https://www.globenewswire.com/news-release/2023/03/27/2634532/0/en/New-Data-from-the-Phase-3b-ESCAPE-TRD-Study-Show-that-Participants-Receiving-SPRAVATO-Esketamine-Nasal-Spray-NS-Achieved-Higher-Response-and-Remission-Rates-Increasing-Over-Time-Co.html
https://www.europeanpharmaceuticalreview.com/news/176876/nasal-spray-could-help-prevent-depression-relapse/
https://www.fiercepharma.com/pharma/jjs-spravato-nasal-spray-bests-former-az-drug-seroquel-treatment-resistant-depression-trial
https://www.clinicaltrialsarena.com/news/janssen-major-depressive-disorder-trial/
https://health.economictimes.indiatimes.com/news/pharma/stigma-in-drug-research-holding-back-new-therapies/94760467
https://www.fiercepharma.com/pharma/did-nice-play-fair-jj-wins-appeal-part-glean-rationale-behind-cost-watchdogs-spravato-snub
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211243
https://www.accesswire.com/663930/NLS-Initiates-Phase-2-Trial-for-Quilience-in-Narcolepsy-and-Announces-First-Patient-Enrolled
https://www.globenewswire.com/news-release/2021/06/10/2245151/0/en/PharmaTher-Provides-Research-and-Development-Update-and-Milestones-for-2021.html
https://www.prnewswire.com/news-releases/american-journal-of-psychiatry-publishes-international-ketamine-and-esketamine-treatment-guidance-led-by-braxia-scientific-ceo-dr-roger-mcintyre-301308890.html
http://www.pharmafile.com/news/570714/janssens-esketamine-nasal-spray-gets-europe-approval-new-indication
https://www.businesswire.com/news/home/20201211005267/en/Janssen-Receives-Positive-CHMP-Opinion-for-SPRAVATO%C2%AE%E2%96%BC-Esketamine-Nasal-Spray-for-the-Rapid-Reduction-of-Depressive-Symptoms-in-a-Psychiatric-Emergency-for-Patients-with-Major-Depressive-Disorder
http://www.pharmafile.com/news/558027/nice-knocks-back-janssens-spravato-nasal-spray-second-time-treatment-resistant-depressio
https://www.globenewswire.com/news-release/2020/08/27/2085022/0/en/Champignon-to-Begin-Offering-Esketamine-Treatment-for-Adults-With-Major-Depressive-Disorder-at-the-Canadian-Rapid-Treatment-Centre-of-Excellence.html
https://www.bnnbloomberg.ca/johnson-johnson-spray-approved-for-treating-suicidal-people-1.1474763
https://markets.businessinsider.com/news/stocks/n-spravato-esketamine-nasal-spray-is-available-for-canadian-patients-1029419342
https://www.fiercepharma.com/marketing/j-j-s-ketamine-depression-drug-spravato-fails-nice-review-over-cost-and-clinical-evidence
http://www.pmlive.com/pharma_news/j_and_j_gets_eu_approval_for_depression_nasal_spray_spravato_1320732
https://www.ema.europa.eu/en/documents/overview/spravato-epar-medicine-overview_en.pdf
https://www.jnj.com/janssen-receives-positive-chmp-opinion-for-spravato-esketamine-nasal-spray-for-adults-with-treatment-resistant-major-depressive-disorder
https://www.prnewswire.com/news-releases/janssen-submits-supplemental-new-drug-application-to-us-fda-for-spravato-esketamine-ciii-nasal-spray-for-the-rapid-reduction-of-depressive-symptoms-in-adults-with-major-depressive-disorder-who-have-active-suicidal-ideation-wi-300930061.html
https://www.fiercepharma.com/pharma/j-j-scores-spravato-trial-win-high-risk-depression-will-doctors-and-payers-buy
https://endpts.com/get-as-much-spravato-as-you-can-trump-orders-va-while-suggesting-jj-should-offer-it-to-veterans-for-free/
https://www.fiercepharma.com/pharma/va-doctors-give-johnson-johnson-s-depression-drug-spravato-half-hearted-backing
https://www.fiercepharma.com/pharma/cost-effectiveness-watchdogs-skewer-novartis-ms-drug-mayzent-and-j-j-s-depression-spray
https://khn.org/news/fdas-approval-of-new-depression-drug-overlooked-red-flags-in-its-testing/
http://www.pharmatimes.com/news/new_data_highlights_value_of_janssens_spravato_1288971
http://www.pmlive.com/pharma_news/stung_by_critics,_j_and_j_says_antidepressant_spravato_saves_money_1289036
https://www.fiercepharma.com/pharma/icer-takes-issue-johnson-johnson-s-spravato-price-questions-breadth-data
https://www.statnews.com/2019/04/04/esketamine-psychedelics-restructure-mental-health-care/
https://www.slashgear.com/the-fda-just-approved-this-groundbreaking-antidepressant-nasal-spray-08569272/
https://www.in-pharmatechnologist.com/Article/2019/03/07/Esketamine-nasal-spray-approved-by-FDA
http://www.pmlive.com/pharma_news/j_and_js_spravato_breaks_depression_drought_at_fda_1280598
https://endpts.com/so-you-just-got-a-btd-for-your-top-drug-dont-be-surprised-to-see-the-enthusiasm-fizzle-fast-among-investors/
https://www.reuters.com/article/us-johnson-johnson-fda/johnson-johnsons-nasal-spray-for-depression-wins-fda-panel-backing-idUSKCN1Q12G5
https://www.bloomberg.com/news/articles/2019-02-08/depression-therapy-with-party-drug-roots-faces-fda-panel-review
https://www.biospace.com/article/j-and-j-s-esketamine-for-depression-faces-an-fda-panel-next-week/
https://www.businesswire.com/news/home/20181010005393/en/Janssen-Submits-European-Marketing-Authorisation-Application-Esketamine
http://www.pharmatimes.com/news/janssen_files_nasal_spray_for_depression_1255351
https://www.prnewswire.com/news-releases/janssen-announces-results-of-esketamine-nasal-spray-phase-3-study-in-patients-with-treatment-resistant-depression-300717094.html
https://endpts.com/jj-racks-up-a-fresh-set-of-positive-efficacy-data-for-depression-drug-esketamine-but-questions-linger-on-safety/
https://www.bloomberg.com/news/articles/2018-05-07/aspen-relocates-production-to-new-79-million-south-africa-plant
https://www.fiercebiotech.com/biotech/j-j-preps-for-esketamine-filing-resistant-depression-despite-a-missed-trial
https://www.washingtonpost.com/news/to-your-health/wp/2018/04/20/nasal-spray-of-party-drug-shows-promise-as-fast-acting-antidepressant-researchers-say/?noredirect=on&utm_term=.ed6cdfa27d1e
https://endpts.com/going-0-for-3-in-phiii-auris-late-stage-changeup-fails-to-save-tinnitus-drug-from-another-disaster/
Market Place
Share 
